FDA Launches Immediate Review of Clinical Trials Involving Cell Transfer to Hostile Countries
The U.S. Food and Drug Administration (FDA) this week announced an immediate review of new...
Cell-therapy
CR Sanjiu Partners with HELP Therapeutics to Advance iPSC-based Heart Failure Therapy
China-based CR Sanjiu (SHE: 000999), a state-owned pharmaceutical company, announced a partnership with Nanjing-based HELP...
HELP Therapeutics’ iPSC-Derived Cardiomyocyte Therapy Enters US Clinical Trials
Nanjing-based HELP Therapeutics Co. Ltd, a clinical-stage cell therapy company, announced that its innovative induced...
JW Therapeutics’ Carteyva Approved by Macau Health Bureau
JW Therapeutics (HKG: 2126), a clinical-stage cell therapy company co-founded in 2016 by Juno Therapeutics...
JW Therapeutics’ Carteyva Receives Fourth sBLA for r/r LBCL
JW Therapeutics (HKG: 2126), a clinical-stage cell therapy company co-founded in 2016 by Juno Therapeutics...
AbelZeta Pharma’s C-CAR168 Secures FDA RMAT Designation for Lupus Treatments
Sino-US biotech AbelZeta Pharma, Inc., based in Rockville, Maryland, and with operations in Shanghai, announced...
CARsgen’s Satricabtagene Autoleucel Granted Priority Review by China’s CDE
China-based CARsgen Therapeutics Holdings Ltd (HKG: 2171) has announced that the Center for Drug Evaluation...
CARsgen’s Satri-Cel Shows Significant Efficacy in Gastric Cancer Study
China-based CARsgen Therapeutics Holdings Limited (HKG: 2171) announced that it has published an abstract of...
AstraZeneca Completes Acquisition of EsoBiotec for Up to USD 1 Billion
UK-based major AstraZeneca (AZ; NASDAQ: AZN) announced the completion of its acquisition of EsoBiotec SA,...
Porton and Hualong Biological Partner to Advance MATC Therapy
Suzhou-based contract development and manufacturing organization (CDMO) Porton Pharma Solutions Ltd. has entered into a...
WuHan Hamilton Biotech’s HUC-MSCs Product Approved for Clinical Trials in Premature Ovarian Failure
China-based WuHan Hamilton Biotechnology Co., Ltd. has announced receiving clinical trial approval from the National...
Porton Pharma Collaborates with Henan Hualong for MATC Therapy Development
China-based Contract Development and Manufacturing Organization (CDMO) Porton Pharma Solutions Ltd has entered into a...
Guangzhou Regenverse Therapeutics Raises RMB 100 Million in Pre-Series A Financing
China-based Guangzhou Regenverse Therapeutics Co., Ltd (former name: Guangzhou Regen Therapeutics Co., Ltd.), a developer...
Oricell Partners with Umoja Biopharma to Develop In Vivo CAR-T Cell Therapies
China-based Oricell Therapeutics Co., Ltd. announced a strategic partnership agreement with US-headquartered Umoja Biopharma Inc....
EndoCell Secures RMB 200 Million in Financing to Advance Islet Regeneration Technology
EndoCell Biotech, a Shanghai-based developer of regenerated islet technology, reportedly completed Series A and Pre-Series...
BMS Q1 2025 Results: Opdivo Sales Up 12% Despite Overall Revenue Decline
US-based multinational Bristol-Myers Squibb (BMS, NYSE: BMY) released its Q1 2025 financial results, showing a...
JW Therapeutics Enters Licensing Pact with Juno Therapeutics for sLVV Process
China-based JW Therapeutics (HKG: 2126), co-founded by Juno Therapeutics Inc. (a Bristol-Myers Squibb company) and...
iMBIORAY Gains NMPA Approval for Phase IITrial of IBR854 in Advanced RCC
Hangzhou-based cancer immunotherapy specialist iMBIORAY has received approval from China’s National Medical Products Administration (NMPA)...
BRL Medicine Secures IND Approval for BRL-301 CAR-T Therapy in R/R B-NHL
Shanghai-based BRL Medicine Inc. has announced that it has received Investigational New Drug (IND) approval...
Johnson & Johnson Reports Q1 2025 Revenue Growth, Led by Innovative Medicines and MedTech
US pharmaceutical giant Johnson & Johnson (J&J, NYSE: JNJ) reported Q1 2025 revenues of USD...